Yen David M, Murray Michael T, Puchalski Robert, Gould Andrew R, Ansley John, Ow Randall A, Moss Jonathan R, England Laura J, Syms Charles A
Specialty Physician Associates, Bethlehem, Pennsylvania, USA.
Camino Ear, Nose & Throat Clinic, San Jose, California, USA.
OTO Open. 2020 Feb 24;4(1):2473974X20903125. doi: 10.1177/2473974X20903125. eCollection 2020 Jan-Mar.
(1) To evaluate safety, tolerability, and technical success of lidocaine iontophoresis and a tympanostomy tube placement system for adults in an office setting and (2) to meet regulatory evidence requirements for new drugs and devices.
Prospective, multicenter, single arm.
Patients were recruited in 8 community-based practices in the United States between June and September 2017.
This study evaluated tympanic membrane anesthesia and tube placement in 30 adults. Anesthesia was achieved via iontophoresis of a lidocaine/epinephrine solution. Tube placement was conducted using an integrated myringotomy and tube delivery system. Tolerability of tube placement was measured using a patient-reported visual analog scale from 0 mm () to 100 mm (). Mean pain score was compared to a performance goal of 45 mm, where statistical superiority represents mild pain or less. Technical success and safety through 3 weeks postprocedure were evaluated.
Twenty-nine (29/30, 96.7%) patients had tube(s) successfully placed in all indicated ears. One patient demonstrated inadequate tympanic membrane anesthesia, and no tube placement was attempted. The mean (SD) pain score of 9.4 (15.7) mm was statistically superior to the performance goal. There were no serious adverse events. Seven nonserious events were related to device, procedure, or drug: inadequate anesthesia (1), vertigo (1), and dizziness (1) at the time of procedure and ear discomfort (1), tube occlusion (2), and medial tube migration (1) postprocedure.
Lidocaine iontophoresis provides acceptable tympanic membrane anesthesia for safe, tolerable, and successful in-office tube placement using an integrated myringotomy and tube delivery system.
(1)评估利多卡因离子导入法及鼓膜造孔置管系统在门诊环境中用于成人的安全性、耐受性及技术成功率;(2)满足新药及新器械的监管证据要求。
前瞻性、多中心、单臂研究。
2017年6月至9月期间在美国8家社区医疗机构招募患者。
本研究评估了30名成人的鼓膜麻醉及置管情况。通过利多卡因/肾上腺素溶液离子导入实现麻醉。使用一体化鼓膜切开及置管系统进行置管。采用患者自报的视觉模拟量表(从0毫米(无疼痛)至100毫米(剧痛))测量置管耐受性。将平均疼痛评分与45毫米的性能目标进行比较,若统计结果显示优越性,则表示疼痛为轻度或更低。评估术后3周内的技术成功率及安全性。
29名(29/30,96.7%)患者的所有指定耳朵均成功置管。1名患者鼓膜麻醉不足,未尝试置管。平均(标准差)疼痛评分为9.4(15.7)毫米,在统计学上优于性能目标。未发生严重不良事件。7起非严重事件与器械、操作或药物有关:操作时麻醉不足(1例)、眩晕(1例)、头晕(1例)以及术后耳部不适(1例)、导管堵塞(2例)和导管向内侧移位(1例)。
利多卡因离子导入法可为使用一体化鼓膜切开及置管系统在门诊安全、耐受且成功地进行鼓膜置管提供可接受的鼓膜麻醉。